ArticleBMC cancer2025
Development of a nomogram for predicting microvascular invasion in patients with hepatocellular carcinoma.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundPreoperative diagnosis of microvascular invasion (MVI) is difficult for patients with hepatocellular carcinoma (HCC). The aim of this study was to develop and validate a nomogram to predict the risk of MVI before surgery.
methodsA total of 661 HCC patients who underwent curative resection were included in the study. Independent risk factors were identified by univariate/multivariate analyses and were built into a nomogram to estimate the risk of MVI. The receiver operating characteristic (ROC) curve, concordance index (c-index), calibration curve and decision curve analysis were used to evaluate the predictive performance of the models.
resultsPrealbumin, gamma-glutamyl transpeptidase, alpha-fetoprotein level, and tumor size were found to be independent risk factors for MVI and formed the basis of the nomogram. The area under the ROC curve (AUC) of the nomogram for predicting MVI was 0.775 (C-index of 0.781) in the training cohort, 0.787 (C-index of 0.785) in the validation cohort, and 0.789 (C-index of 0.790) in the external validation cohort. The nomogram exhibited favorable calibration performance, and decision curve analysis demonstrated that the nomogram has clinical value.
conclusionsWe developed a new nomogram that used basic clinical and laboratory variables to predict the probability of MVI before surgery for HCC patients. This nomogram can help clinicians choose appropriate treatment procedures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.